Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19024392 | 1.00 | KDM4E (0.46) | KDM4EKMT2AL3MBTL1CYSLTR2CYSLTR1 | |
| SCHEMBL19024404 | 0.81 | KMT2A (0.51) | KDM4EKMT2AL3MBTL1CNR1CNR2 | |
| SCHEMBL9363530 | 0.81 | KMT2A (0.51) | KDM4EKMT2AL3MBTL1CNR1CNR2 | |
| SCHEMBL28963762 | 0.76 | KDM4E (0.57) | KDM4EKMT2AL3MBTL1CNR1CNR2 | |
| SCHEMBL28963638 | 0.76 | KDM4E (0.57) | KDM4EKMT2AL3MBTL1CNR1CNR2 | |
| SCHEMBL33526666 | 0.76 | SLC16A3 (0.46) | KDM4EKMT2AL3MBTL1LIPGCNR1 | |
| SCHEMBL284843 | 0.76 | SLC16A3 (0.46) | KDM4EKMT2AL3MBTL1LIPGCNR1 | |
| SCHEMBL29615063 | 0.76 | SLC16A3 (0.46) | KDM4EKMT2AL3MBTL1LIPGCNR1 | |
| SCHEMBL60812 | 0.76 | SLC16A3 (0.46) | KDM4EKMT2AL3MBTL1LIPGCNR1 | |
| SCHEMBL9619173 | 0.76 | SLC16A3 (0.46) | KDM4EKMT2AL3MBTL1LIPGCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257922-B1 | LUBRICANT COMPOSITION, USE THEREOF AND ALIPHATIC ETHER COMPOUND | MORESCO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-9920274-B2 | Lubricant composition, use thereof and aliphatic ether compound | MORESCO CORPORATION (JP) | 2018-03-20 | — | — | US | disclosed |
| EP-3257922-A1 | LUBRICANT COMPOSITION, USE THEREOF AND ALIPHATIC ETHER COMPOUND | Moresco Corporation (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-20170183598-A1 | LUBRICANT COMPOSITION, USE THEREOF AND ALIPHATIC ETHER COMPOUND | MORESCO CORPORATION (JP) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183598-A1 | LUBRICANT COMPOSITION, USE THEREOF AND ALIPHATIC ETHER COMPOUND | PHOSPHO1, PLTP, NAPEPLD | KDM4E 1617/4885KMT2A 1683/4885L3MBTL1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.